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Background: Obesity is characterized by low-grade chronic inflammation, elevated circulating 
cytokines, and hepatic overexpression of suppressor of cytokine signaling (SOCS) proteins, which 
are negative regulators of the JAK/STAT pathway activated by pro-inflammatory cytokines, including 
the tumor necrosis factor-alpha (TNF-alpha). SOCS3 is also implicated in hypertriglyceridemia 
associated to insulin-resistance (IR) (1). Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) levels 
are frequently found to be positively correlated to IR and plasma very low-density lipoprotein-
triglycerides (VLDL-TG) concentrations (2). AIM: To investigate, in a condition of IR, the role of SOCS3 
on de novo lipogenesis, cholesterol biosynthesis and PCSK9 expression in human HepG2 cell line. 
Results: To resemble a condition of chronic-inflammation (characterized by SOCS3 activation), we 
stimulated HepG2 cells with TNF-alpha and resistin and then generated an HepG2 cell line 
overexpressing SOCS3 (HepG2SOCS3). TNF-alpha and resistin induced both SOCS3 and PCSK9 
expression in HepG2 cells and for TNF-alpha. These effects were inhibited by transfection with siRNA 
anti-STAT3, suggesting the involvement of the JAK/STAT pathway. In parallel retroviral SOCS3 
overexpression determined a complete abrogation of STAT3 phosphorylation. HepG2SOCS3 showed 
higher de novo lipogenesis (induction of fatty-acid synthase (FAS) mRNA by 3.59±0.40 fold; stearoyl-
CoA desaturase (SCD-1) mRNA by 1.92±0.12 fold; and apolipoproteinB (apoB) secretion by 
3.47±0.09 fold). These responses were associated with significant increase of SCD-1 protein, 
activation of SREBP-1, accumulation of cellular TG, and secretion of apoB. HepG2SOCS3 cells express 
higher levels of PCSK9 mRNA (3.48±0.35 fold) and protein secretion (2.18±1.13 fold) No relevant 
changes of HMG-CoA reductase, low-density lipoprotein receptor levels and cholesterol 
biosynthesis were found. In addition, TNF-alpha significantly induced SCD-1, apoB and FAS mRNA 
levels (2.110.43, 1.600.33 and 1.390.21 fold, respectively). Insulin stimulation further induced 
FAS, SREBP-1 and PCSK9 mRNA levels to a similar extent in control and SOCS3-overexpressing cells, 
although the overall mRNA levels of these genes were significantly higher in HepG2SOCS3 cells. Akt 
and IRS-1 phosphorylation in response to insulin was attenuated in HepG2SOCS3, supporting IRS-1 
inhibition as the mechanism of abrogated Akt, and STAT3 phosphorylation. Conclusions: Our data 
provide evidence for the JAK/STAT dependent expression of PCSK9 in hepatic cell line, suggesting 
the potential molecular basis of the direct relationship between PCSK9, triglycerides levels and IR 
observed in clinical settings. 
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